EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD4-mimetics sensitize HIV-infected cells to ADCC mediated by plasma from persons with early-stage HIV-1 infection

Shilei Ding, Alexandra Tauzin, Delia Pinto-Santini, Sayan Dasgupta, Derek Yang, William D Tolbert, Monika Chandravanshi, Mehdi Benlarbi, Myriam Verly, Javier R Lama iD, Donna M Huryn, Amos B Smith und 3 weitere

Journal of Virology · 19.08.2025 · 99 (8)

DOI: 10.1128/jvi.00858-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 19.08.2025. Verfasst von Shilei Ding und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du CHUM, Montreal, Québec, Canada. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Antibody-Dependent Cell Cytotoxicity, HIV Antibodies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, CIHR, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The viral reservoir in long-lived memory CD4+ cells, established in the early stages of HIV infection, represents the main obstacle to an HIV cure. Some strategies being developed to target the reservoir rely on rendering HIV-1 envelope glycoproteins (Env) visible to the immune system. Small molecule CD4-mimetics (CD4mcs) expose vulnerable Env epitopes, which can be targeted by non-neutralizing antibodies (nnAbs) that are abundant in the plasma of people living with HIV (PLWH) and can mediate antibody-dependent cellular cytotoxicity (ADCC). Administration of CD4mcs in combination with plasma from PLWH or nnAbs efficiently reduces the size of the HIV-1 reservoir and postpones viral rebound upon antiretroviral therapy (ART) interruption in humanized mice. However, it remains unclear when these nnAbs are elicited after HIV infection. In this study, we collected longitudinal plasma samples before acquisition, at diagnosis, and at multiple time points up to 33 weeks after the estimated date of detectable infection (EDDI) and before ART treatment initiation. We found that plasma samples collected as early as 3 to 10 weeks after EDDI neutralized viral particles and mediated ADCC in the presence of the CJF-III-288 CD4mc. Recognition of HIV-1-infected cells and ADCC progressively increased over time, reaching a plateau by 19–25 weeks after EDDI. ADCC activity increased concomitantly with the elicitation of anti-gp120 and anti-gp41 CD4-induced (CD4i) Abs and improved over time with the appearance of anti-coreceptor binding site antibodies. Our results show that CD4i nnAbs, able to eliminate HIV-1-infected cells in the presence of CD4mc, are elicited within a few weeks after HIV acquisition. IMPORTANCE A viral reservoir is established at the early stages of HIV-1 infection. This reservoir persists during antiretroviral therapy (ART) treatment, and viral rebound is observed after ART interruption. New strategies are needed to reduce the size of the viral reservoir and prevent virus rebound. Several families of non-neutralizing antibodies, which are abundant in plasma from people living with HIV-1, neutralize viral particles and mediate the elimination of HIV-1-infected cells through antibody-dependent cellular cytotoxicity (ADCC) when combined with CD4-mimetic compounds. The presence of non-neutralizing antibodies in plasma during early-stage HIV-1 infection would support the use of CD4-mimetic compounds as an early intervention to decrease the size of the latent HIV-1 reservoir by eliminating infected cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Antibody-Dependent Cell CytotoxicityHIV AntibodiesCD4-Positive T-LymphocytesCD4 AntigensHumansHIV Envelope Protein gp120MaleFemaleAdultEpitopesAntibodies, NeutralizingMiddle Aged

Stichwörter der Autor:innen

ADCCCD4-mimetic compoundsHIV-1plasma from PLWH

Substanzen

HIV AntibodiesCD4 AntigensHIV Envelope Protein gp120EpitopesAntibodies, Neutralizing

Autor:innen und Institutionen

  • Centre de Recherche du CHUM, Montreal, Québec, Canada.
  • Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Québec, Canada.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Asociación Civil Impacta Salud y Educación, Lima, Peru.

ORCID-Profile: Javier R Lama, Marzena Pazgier, Andrés Finzi, Ann Duerr

Förderung

  • NIAID NIH HHS
  • CIHR
  • NIH HHS
  • Canadian Institutes of Health Research
  • National Institutes of Health

Zitieren

APA

Ding, S., Tauzin, A., Pinto-Santini, D., Dasgupta, S., Yang, D., Tolbert, W. D., Chandravanshi, M., Benlarbi, M., Verly, M., Lama, J. R., Huryn, D. M., Smith, A. B., Pazgier, M., Finzi, A., & Duerr, A. (2025). CD4-mimetics sensitize HIV-infected cells to ADCC mediated by plasma from persons with early-stage HIV-1 infection. Journal of Virology, 99(8). https://doi.org/10.1128/jvi.00858-25

Vancouver

Ding S, Tauzin A, Pinto-Santini D, Dasgupta S, Yang D, Tolbert WD, et al. CD4-mimetics sensitize HIV-infected cells to ADCC mediated by plasma from persons with early-stage HIV-1 infection. Journal of Virology. 2025;99(8). doi:10.1128/jvi.00858-25

BibTeX
@article{Ding2025,
  author = {Ding, Shilei and Tauzin, Alexandra and Pinto-Santini, Delia and Dasgupta, Sayan and Yang, Derek and Tolbert, William D and Chandravanshi, Monika and Benlarbi, Mehdi and Verly, Myriam and Lama, Javier R and Huryn, Donna M and Smith, Amos B and Pazgier, Marzena and Finzi, Andrés and Duerr, Ann},
  title = {CD4-mimetics sensitize HIV-infected cells to ADCC mediated by plasma from persons with early-stage HIV-1 infection},
  journal = {Journal of Virology},
  year = {2025},
  volume = {99},
  number = {8},
  doi = {10.1128/jvi.00858-25}
}
Kostenlos starten →